Monash IVF Group (ASX:MVF) has entered a critical period of negotiation following a revised, non-binding indicative proposal from a high-profile consortium.
The suitor, comprising Genesis Capital Investment Management and WHSP Holdings (Soul Patts), has increased its cash offer to $0.90 per share, a step up from the initial $0.80 bid rejected by the company in late 2025.
The latest move marks a determined effort by the consortium—which already maintains a substantial 19.6% stake in the fertility provider—to acquire 100% of the company through a scheme of arrangement.
The revised proposal comes with a clear ultimatum: the consortium has stated this $0.90 figure represents their "highest amount", contingent on no competing offers emerging.
Furthermore, the offer carries a strict deadline, remaining valid only until the close of business on April 21.
This tight timeframe places immense pressure on the Monash IVF board to conduct a swift yet thorough evaluation.
Several stringent conditions underpin the bid, including a request for four weeks of exclusive due diligence with no fiduciary exceptions and the requirement for a unanimous board recommendation.
In response, Monash IVF has mobilised its defence, appointing Macquarie Capital and Clayton Utz as financial and legal advisers, respectively.
While the board assesses the merits of the deal, they have advised shareholders that no immediate action is required, reminding the market that there is no certainty these discussions will culminate in a final transaction.
At the time of reporting, Monash IVF Group’s share price was $0.76.